{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T03:11:41Z","timestamp":1770693101074,"version":"3.49.0"},"reference-count":136,"publisher":"Oxford University Press (OUP)","issue":"1175","license":[{"start":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T00:00:00Z","timestamp":1757721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Circulating tumour cells (CTCs) have emerged as a promising biomarker for assessing prognosis and predicting therapeutic efficacy in various cancers, including metastatic prostate cancer. However, predicting patient response to treatment, including radiation therapy (RT), remains a significant clinical challenge. This review explores the value of CTCs as prognostic markers in RT for prostate cancer, discussing their detection methods, biological significance, clinical relevance, and future implications.<\/jats:p>","DOI":"10.1093\/bjr\/tqaf224","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T19:02:28Z","timestamp":1758308548000},"page":"1899-1911","source":"Crossref","is-referenced-by-count":1,"title":["Circulating tumour cells for the prediction of the response to radiation therapy in prostate cancer"],"prefix":"10.1093","volume":"98","author":[{"given":"Camille","family":"Landry","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Institut de Canc\u00e9rologie de l\u2019Ouest , Saint-Herblain, 44805,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daria","family":"Klusa","sequence":"additional","affiliation":[{"name":"Tumour Heterogeneity and Precision Medicine\u201d Laboratory, Institut de Canc\u00e9rologie de l\u2019Ouest , Saint-Herblain, 44805,","place":["France"]},{"name":"Biological Sciences and Biotechnologies Unit, Nantes Universit\u00e9, CNRS, UMR 6286, US2B , Nantes, 44322,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Cochonneau","sequence":"additional","affiliation":[{"name":"Tumour Heterogeneity and Precision Medicine\u201d Laboratory, Institut de Canc\u00e9rologie de l\u2019Ouest , Saint-Herblain, 44805,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2094-1708","authenticated-orcid":false,"given":"St\u00e9phane","family":"Supiot","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Institut de Canc\u00e9rologie de l\u2019Ouest , Saint-Herblain, 44805,","place":["France"]},{"name":"Tumour Heterogeneity and Precision Medicine\u201d Laboratory, Institut de Canc\u00e9rologie de l\u2019Ouest , Saint-Herblain, 44805,","place":["France"]},{"name":"Biological Sciences and Biotechnologies Unit, Nantes Universit\u00e9, CNRS, UMR 6286, US2B , Nantes, 44322,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7777-0669","authenticated-orcid":false,"given":"Dominique","family":"Heymann","sequence":"additional","affiliation":[{"name":"Tumour Heterogeneity and Precision Medicine\u201d Laboratory, Institut de Canc\u00e9rologie de l\u2019Ouest , Saint-Herblain, 44805,","place":["France"]},{"name":"Biological Sciences and Biotechnologies Unit, Nantes Universit\u00e9, CNRS, UMR 6286, US2B , Nantes, 44322,","place":["France"]},{"name":"School of Medicine and Population Health, University of Sheffield, Medical School , Sheffield, S10 2RX,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,9,13]]},"reference":[{"key":"2025112712264191400_tqaf224-B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"2025112712264191400_tqaf224-B2","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1007\/s00345-018-2403-7","article-title":"The utility of PET-based imaging for prostate cancer biochemical recurrence: a systematic review and meta-analysis","volume":"37","author":"Sathianathen","year":"2019","journal-title":"World J Urol"},{"key":"2025112712264191400_tqaf224-B3","doi-asserted-by":"publisher","first-page":"1494723","DOI":"10.3389\/fonc.2025.1494723","article-title":"Circulating tumor cell markers for early detection and drug resistance assessment through liquid biopsy","volume":"15","author":"Yadav","year":"2025","journal-title":"Front Oncol"},{"key":"2025112712264191400_tqaf224-B4","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3389\/fonc.2016.00202","article-title":"The challenges of detecting circulating tumor cells in sarcoma","volume":"6","author":"Tellez-Gabriel","year":"2016","journal-title":"Front Oncol"},{"key":"2025112712264191400_tqaf224-B5","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1091\/mbc.E08-10-1076","article-title":"ZEB1 enhances transendothelial migration and represses the epithelial phenotype of prostate cancer cells","volume":"20","author":"Drake","year":"2009","journal-title":"Mol Biol Cell"},{"key":"2025112712264191400_tqaf224-B6","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1186\/s12885-021-08405-3","article-title":"Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patients","volume":"21","author":"Chong","year":"2021","journal-title":"BMC Cancer"},{"key":"2025112712264191400_tqaf224-B7","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.ccell.2024.11.009","article-title":"Advances in liquid biopsy: from exploration to practical application","volume":"43","author":"Alix-Panabi\u00e8res","year":"2025","journal-title":"Cancer Cell"},{"key":"2025112712264191400_tqaf224-B8","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41571-024-00967-y","article-title":"Minimal residual disease as a target for liquid biopsy in patients with solid tumours","volume":"22","author":"Pantel","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"2025112712264191400_tqaf224-B9","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.eururo.2022.08.010","article-title":"Analysis of BRCA2 copy number loss and genomic instability in circulating tumor cells from patients with metastatic castration-resistant prostate cancer","volume":"83","author":"Barnett","year":"2023","journal-title":"Eur Urol"},{"key":"2025112712264191400_tqaf224-B10","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1158\/1078-0432.CCR-20-3471","article-title":"Circulating tumor cell chromosomal instability and neuroendocrine phenotype by immunomorphology and poor outcomes in men with mCRPC treated with abiraterone or enzalutamide","volume":"27","author":"Brown","year":"2021","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"2025112712264191400_tqaf224-B11","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1158\/2159-8290.CD-24-1509","article-title":"High-purity CTC RNA sequencing identifies prostate cancer lineage phenotypes prognostic for clinical outcomes","volume":"15","author":"Sharifi","year":"2025","journal-title":"Cancer Discov"},{"key":"2025112712264191400_tqaf224-B12","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1093\/jnci\/45.4.773","article-title":"Metastasis: quantitative analysis of distribution and fate of tumor emboli labeled with 125I-5-Iodo-2\u2032 -deoxyuridine23","volume":"45","author":"Fidler","year":"1970","journal-title":"JNCI J Natl Cancer Inst"},{"key":"2025112712264191400_tqaf224-B13","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.cell.2014.07.013","article-title":"Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis","volume":"158","author":"Aceto","year":"2014","journal-title":"Cell"},{"key":"2025112712264191400_tqaf224-B14","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1373\/clinchem.2015.249706","article-title":"Circulating tumor cells: a review of Non-EpCAM-based approaches for cell enrichment and isolation","volume":"62","author":"Gabriel","year":"2016","journal-title":"Clin Chem"},{"key":"2025112712264191400_tqaf224-B15","doi-asserted-by":"publisher","first-page":"446","DOI":"10.3978\/j.issn.2072-1439.2012.08.15","article-title":"Detection methods of circulating tumor cells","volume":"4","author":"Pantel","year":"2012","journal-title":"J Thorac Dis"},{"key":"2025112712264191400_tqaf224-B16","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/nprot.2014.006","article-title":"Full-length RNA-seq from single cells using smart-seq2","volume":"9","author":"Picelli","year":"2014","journal-title":"Nat Protoc"},{"key":"2025112712264191400_tqaf224-B17","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1126\/science.aab0917","article-title":"RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance","volume":"349","author":"Miyamoto","year":"2015","journal-title":"Science (1979)"},{"key":"2025112712264191400_tqaf224-B18","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.1158\/1078-0432.CCR-05-2821","article-title":"Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival","volume":"12","author":"Hayes","year":"2006","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"2025112712264191400_tqaf224-B19","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1200\/JCO.2007.15.8923","article-title":"Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer","volume":"26","author":"Cohen","year":"2008","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2025112712264191400_tqaf224-B20","doi-asserted-by":"publisher","first-page":"6302","DOI":"10.1158\/1078-0432.CCR-08-0872","article-title":"Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer","volume":"14","author":"de Bono","year":"2008","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"2025112712264191400_tqaf224-B21","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1002\/ijc.25819","article-title":"Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non-small-cell lung carcinoma: comparison of the efficacy of the CellSearch AssayTM and the isolation by size of epithelial tumor cell method","volume":"129","author":"Hofman","year":"2011","journal-title":"Int J Cancer"},{"key":"2025112712264191400_tqaf224-B22","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/bjc.2011.294","article-title":"A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas","volume":"105","author":"Farace","year":"2011","journal-title":"Br J Cancer"},{"key":"2025112712264191400_tqaf224-B23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/cyto.b.20065","article-title":"Comparison of two methods for enumerating circulating tumor cells in carcinoma patients","volume":"68","author":"Balic","year":"2005","journal-title":"Cytometry B Clin Cytom"},{"key":"2025112712264191400_tqaf224-B24","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1002\/cyto.a.23571","article-title":"The ParsortixTM cell separation system\u2014a versatile liquid biopsy platform","volume":"93","author":"Miller","year":"2018","journal-title":"Cytometry A"},{"key":"2025112712264191400_tqaf224-B25","doi-asserted-by":"publisher","first-page":"51","DOI":"10.20517\/cdr.2024.149","article-title":"CIRCUS: CIRCUlating tumour cells in soft tissue Sarcoma\u2014a short report","volume":"7","author":"Young","year":"2024","journal-title":"Cancer Drug Resist Alhambra Calif"},{"key":"2025112712264191400_tqaf224-B26","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1200\/JCO.2017.75.2998","article-title":"Circulating tumor cell number as a response measure of prolonged survival for metastatic castration-resistant prostate cancer: a comparison with prostate-specific antigen across five randomized phase III clinical trials","volume":"36","author":"Heller","year":"2018","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2025112712264191400_tqaf224-B27","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1200\/JCO.2013.51.7417","article-title":"Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer","volume":"32","author":"Goldkorn","year":"2014","journal-title":"J Clin Oncol"},{"key":"2025112712264191400_tqaf224-B28","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/iju.14801","article-title":"Presence of CD133-positive circulating tumor cells predicts worse progression-free survival in patients with metastatic castration-sensitive prostate cancer","volume":"29","author":"Yang","year":"2022","journal-title":"Int J Urol Off J Jpn Urol Assoc"},{"key":"2025112712264191400_tqaf224-B29","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.3390\/cells8091067","article-title":"Detection of androgen receptor variant 7 (ARV7) mRNA levels in EpCAM-enriched CTC fractions for monitoring response to androgen targeting therapies in prostate cancer","volume":"8","author":"Hille","year":"2019","journal-title":"Cells"},{"key":"2025112712264191400_tqaf224-B30","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.eururo.2019.04.006","article-title":"Clinical utility of circulating tumour cell androgen receptor splice variant-7 status in metastatic castration-resistant prostate cancer","volume":"76","author":"Sharp","year":"2019","journal-title":"Eur Urol"},{"key":"2025112712264191400_tqaf224-B31","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1158\/1078-0432.CCR-23-3083","article-title":"Impact of circulating tumor cell-expressed prostate-specific membrane antigen and prostate-specific antigen transcripts in different stages of prostate cancer","volume":"30","author":"Cho","year":"2024","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"2025112712264191400_tqaf224-B32","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1200\/JCO.21.00169","article-title":"Prospective evaluation of clinical outcomes using a multiplex liquid biopsy targeting diverse resistance mechanisms in metastatic prostate cancer","volume":"39","author":"Sperger","year":"2021","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2025112712264191400_tqaf224-B33","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.3390\/cancers11091365","article-title":"Role of circulating tumor cells (CTC), androgen receptor full length (AR-FL) and androgen receptor splice variant 7 (AR-V7) in a prospective cohort of castration-resistant metastatic prostate cancer patients","volume":"11","author":"Cattrini","year":"2019","journal-title":"Cancers (Basel)"},{"key":"2025112712264191400_tqaf224-B34","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.3390\/cancers13112750","article-title":"Diversity of epithelial-mesenchymal phenotypes in circulating tumour cells from prostate cancer patient-derived xenograft models","volume":"13","author":"Hassan","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025112712264191400_tqaf224-B35","doi-asserted-by":"publisher","first-page":"39736","DOI":"10.1038\/srep39736","article-title":"Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients","volume":"6","author":"Kuske","year":"2016","journal-title":"Sci Rep"},{"key":"2025112712264191400_tqaf224-B36","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1158\/1078-0432.CCR-15-0137","article-title":"The initial detection and partial characterization of circulating tumor cells in neuroendocrine prostate cancer","volume":"22","author":"Beltran","year":"2016","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"2025112712264191400_tqaf224-B37","doi-asserted-by":"publisher","first-page":"802","DOI":"10.3390\/cancers11060802","article-title":"Analysis of circulating tumor cells in patients with non-metastatic high-risk prostate cancer before and after radiotherapy using three different enumeration assays","volume":"11","author":"Budna-Tukan","year":"2019","journal-title":"Cancers (Basel)"},{"key":"2025112712264191400_tqaf224-B38","doi-asserted-by":"publisher","first-page":"17501","DOI":"10.1038\/s41598-024-68336-4","article-title":"Combined microfluidic enrichment and staining workflow for single-cell analysis of circulating tumor cells in metastatic prostate cancer patients","volume":"14","author":"L\u00f8ppke","year":"2024","journal-title":"Sci Rep"},{"key":"2025112712264191400_tqaf224-B39","doi-asserted-by":"publisher","first-page":"49329","DOI":"10.18632\/oncotarget.17632","article-title":"EMT circulating tumor cells detected by cell-surface vimentin are associated with prostate cancer progression","volume":"8","author":"Satelli","year":"2017","journal-title":"Oncotarget"},{"key":"2025112712264191400_tqaf224-B40","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/pcan.2015.36","article-title":"The significance of circulating tumor cells in prostate cancer patients undergoing adjuvant or salvage radiation therapy","volume":"18","author":"Lowes","year":"2015","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2025112712264191400_tqaf224-B41","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/s41588-025-02205-2","article-title":"Phylogenetic inference reveals clonal heterogeneity in circulating tumor cell clusters","volume":"57","author":"Gremmelspacher","year":"2025","journal-title":"Nat Genet"},{"key":"2025112712264191400_tqaf224-B42","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3390\/life12020165","article-title":"Predictive value of circulating tumor cells detected by ISET\u00ae in patients with Non-Metastatic prostate cancer undergoing radical prostatectomy","volume":"12","author":"Garrido Castillo","year":"2022","journal-title":"Life Basel Switz"},{"key":"2025112712264191400_tqaf224-B43","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1002\/cyto.a.23687","article-title":"DEPArrayTM system: an automatic image-based sorter for isolation of pure circulating tumor cells","volume":"93","author":"Di Trapani","year":"2018","journal-title":"Cytom Part J Int Soc Anal Cytol"},{"key":"2025112712264191400_tqaf224-B44","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1002\/cncr.21324","article-title":"The role of radiotherapy in cancer treatment","volume":"104","author":"Delaney","year":"2005","journal-title":"Cancer"},{"key":"2025112712264191400_tqaf224-B45","doi-asserted-by":"publisher","first-page":"20230334","DOI":"10.1259\/bjr.20230334","article-title":"The use of radiotherapy, surgery and chemotherapy in the curative treatment of cancer: results from the FORTY (favourable outcomes from RadioTherapY) project","volume":"96","author":"Mee","year":"2023","journal-title":"Br J Radiol"},{"key":"2025112712264191400_tqaf224-B46","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.prro.2016.08.001","article-title":"Palliative radiation therapy for bone metastases: update of an ASTRO evidence-based guideline","volume":"7","author":"Lutz","year":"2017","journal-title":"Pract Radiat Oncol"},{"key":"2025112712264191400_tqaf224-B47","doi-asserted-by":"publisher","first-page":"683042","DOI":"10.3389\/fonc.2021.683042","article-title":"Patient-Reported outcomes assessing the impact of palliative radiotherapy on quality of life and symptom burden in head and neck cancer patients: a systematic review","volume":"11","author":"Fabian","year":"2021","journal-title":"Front Oncol"},{"key":"2025112712264191400_tqaf224-B48","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.ijrobp.2013.10.033","article-title":"Mobilization of viable tumor cells into the circulation during radiation therapy","volume":"88","author":"Martin","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025112712264191400_tqaf224-B49","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.bbrc.2017.08.053","article-title":"Real-time monitoring of circulating tumor cell (CTC) release after nanodrug or tumor radiotherapy using in vivo flow cytometry","volume":"492","author":"Koonce","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"2025112712264191400_tqaf224-B50","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/nrclinonc.2016.128","article-title":"Does the mobilization of circulating tumour cells during cancer therapy cause metastasis?","volume":"14","author":"Martin","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"2025112712264191400_tqaf224-B51","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.celrep.2014.06.011","article-title":"Recruitment of circulating breast cancer cells is stimulated by radiotherapy","volume":"8","author":"Vilalta","year":"2014","journal-title":"Cell Rep"},{"key":"2025112712264191400_tqaf224-B52","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1158\/2159-8290.CD-21-0932","article-title":"Tumor ENPP1 (CD203a)\/haptoglobin axis exploits myeloid-derived suppressor cells to promote post-radiotherapy local recurrence in breast cancer","volume":"12","author":"Ruiz-Fern\u00e1ndez de C\u00f3rdoba","year":"2022","journal-title":"Cancer Discov"},{"key":"2025112712264191400_tqaf224-B53","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1186\/s12885-019-6219-7","article-title":"Ionizing radiation increases the endothelial permeability and the transendothelial migration of tumor cells through ADAM10-activation and subsequent degradation of VE-cadherin","volume":"19","author":"Kouam","year":"2019","journal-title":"BMC Cancer"},{"key":"2025112712264191400_tqaf224-B54","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1158\/1078-0432.CCR-19-2158","article-title":"Circulating tumor cells are associated with recurrent disease in early stage non-small cell lung cancer treated with stereotactic body radiation therapy","volume":"26","author":"Frick","year":"2020","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"2025112712264191400_tqaf224-B55","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3390\/ijms18010128","article-title":"Perioperative search for circulating tumor cells in patients undergoing prostate brachytherapy for clinically nonmetastatic prostate cancer","volume":"18","author":"Tsumura","year":"2017","journal-title":"Int J Mol Sci"},{"key":"2025112712264191400_tqaf224-B56","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.ijrobp.2023.02.021","article-title":"Detection of pretreatment circulating tumor DNA predicts recurrence after high-dose proton beam therapy for early-stage non-small cell lung cancer","volume":"116","author":"Nakamura","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025112712264191400_tqaf224-B57","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.3390\/cancers16051008","article-title":"Proton treatment suppresses exosome production in head and neck squamous cell carcinoma","volume":"16","author":"Chimote","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2025112712264191400_tqaf224-B58","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.eururo.2016.07.051","article-title":"Circulating tumor cells in a phase 3 study of docetaxel and prednisone with or without lenalidomide in metastatic castration-resistant prostate cancer","volume":"71","author":"Vogelzang","year":"2017","journal-title":"Eur Urol"},{"key":"2025112712264191400_tqaf224-B59","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1158\/1078-0432.CCR-20-3587","article-title":"Baseline circulating tumor cell count as a prognostic marker of PSA response and disease progression in metastatic Castrate-Sensitive prostate cancer (SWOG S1216)","volume":"27","author":"Goldkorn","year":"2021","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"2025112712264191400_tqaf224-B60","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1172\/JCI122819","article-title":"Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer","volume":"129","author":"Sharp","year":"2019","journal-title":"J Clin Invest"},{"key":"2025112712264191400_tqaf224-B61","doi-asserted-by":"publisher","first-page":"036003","DOI":"10.1088\/1478-3975\/ab073a","article-title":"Androgen receptor nuclear localization correlates with AR-V7 mRNA expression in circulating tumor cells (CTCs) from metastatic castration resistance prostate cancer patients","volume":"16","author":"Worroll","year":"2019","journal-title":"Phys Biol"},{"key":"2025112712264191400_tqaf224-B62","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1097\/JU.0000000000003892","article-title":"Salvage therapy for prostate cancer: AUA\/ASTRO\/SUO guideline part I: introduction and treatment decision-making at the time of suspected biochemical recurrence after radical prostatectomy","volume":"211","author":"Morgan","year":"2024","journal-title":"J Urol"},{"key":"2025112712264191400_tqaf224-B63","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO phoenix consensus conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025112712264191400_tqaf224-B64","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.radonc.2016.10.026","article-title":"The dose-response of salvage radiotherapy following radical prostatectomy: a systematic review and meta-analysis","volume":"121","author":"King","year":"2016","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"2025112712264191400_tqaf224-B65","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1007\/s00432-014-1775-3","article-title":"Circulating tumor cell detection in high-risk non-metastatic prostate cancer","volume":"140","author":"Loh","year":"2014","journal-title":"J Cancer Res Clin Oncol"},{"key":"2025112712264191400_tqaf224-B66","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3390\/cancers12010160","article-title":"Circulating tumor cells as a marker of disseminated disease in patients with newly diagnosed high-risk prostate cancer","volume":"12","author":"Cie\u015blikowski","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2025112712264191400_tqaf224-B67","doi-asserted-by":"publisher","first-page":"608","DOI":"10.3390\/jpm13040608","article-title":"Baseline CTC count as a predictor of long-term outcomes in high-risk prostate cancer","volume":"13","author":"Cie\u015blikowski","year":"2023","journal-title":"J Pers Med"},{"key":"2025112712264191400_tqaf224-B68","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.3390\/ijms26041548","article-title":"Circulating epithelial tumor cells (CETC\/CTC) in prostate cancer: potential prognostic marker for the risk of recurrence during radiotherapy","volume":"26","author":"Schott","year":"2025","journal-title":"Int J Mol Sci"},{"key":"2025112712264191400_tqaf224-B69","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30010021","article-title":"Increased circulating epithelial tumor cells (CETC\/CTC) over the course of adjuvant radiotherapy is a predictor of less favorable outcome in patients with early-stage breast cancer","volume":"30","author":"M\u00e4urer M, Schott D, Pizon M,","year":"2022","journal-title":"Curr Oncol Tor Ont"},{"key":"2025112712264191400_tqaf224-B70","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1016\/j.ijrobp.2020.07.2076","article-title":"Temporal changes of circulating tumor cells in prostate cancer patients after radiation therapy","volume":"108","author":"Giret","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025112712264191400_tqaf224-B71","doi-asserted-by":"publisher","first-page":"844","DOI":"10.3332\/ecancer.2018.844","article-title":"The presence of secondary circulating prostate tumour cells determines the risk of biochemical relapse for patients with low- and intermediate-risk prostate cancer who are treated only with external radiotherapy","volume":"12","author":"Murray","year":"2018","journal-title":"Ecancermedicalscience"},{"key":"2025112712264191400_tqaf224-B72","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3109\/0284186X.2015.1037013","article-title":"Very low rate of circulating tumour cells (CTCs) in patients with PSA recurrence after radical prostatectomy referred to salvage radiotherapy","volume":"55","author":"Gunnlaugsson","year":"2016","journal-title":"Acta Oncol"},{"key":"2025112712264191400_tqaf224-B73","doi-asserted-by":"publisher","first-page":"5649","DOI":"10.1158\/0008-5472.CAN-10-1040","article-title":"AACR centennial series: the biology of cancer metastasis: historical perspective","volume":"70","author":"Talmadge","year":"2010","journal-title":"Cancer Res"},{"key":"2025112712264191400_tqaf224-B74","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nature14347","article-title":"The evolutionary history of lethal metastatic prostate cancer","volume":"520","author":"Gundem","year":"2015","journal-title":"Nature"},{"key":"2025112712264191400_tqaf224-B75","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet Lond Engl"},{"key":"2025112712264191400_tqaf224-B76","doi-asserted-by":"publisher","first-page":"e173501","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non\u2013small-cell lung cancer: a phase 2 randomized clinical trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol"},{"key":"2025112712264191400_tqaf224-B77","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study","volume":"37","author":"Gomez","year":"2019","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2025112712264191400_tqaf224-B78","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet Lond Engl"},{"key":"2025112712264191400_tqaf224-B79","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.eururo.2018.09.008","article-title":"Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial","volume":"75","author":"Boev\u00e9","year":"2019","journal-title":"Eur Urol"},{"key":"2025112712264191400_tqaf224-B80","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/S0140-6736(24)01865-8","article-title":"Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design","volume":"404","author":"Bossi","year":"2024","journal-title":"Lancet"},{"key":"2025112712264191400_tqaf224-B81","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025112712264191400_tqaf224-B82","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1038\/bjc.2017.103","article-title":"Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study","volume":"116","author":"Triggiani","year":"2017","journal-title":"Br J Cancer"},{"key":"2025112712264191400_tqaf224-B83","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1200\/JCO.22.00644","article-title":"Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials","volume":"40","author":"Deek","year":"2022","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2025112712264191400_tqaf224-B84","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1200\/JCO.2020.38.6_suppl.10","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): five-year results of a randomized phase II trial","volume":"38","author":"Ost","year":"2020","journal-title":"JCO"},{"key":"2025112712264191400_tqaf224-B85","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1748-717X-9-135","article-title":"Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence","volume":"9","author":"Decaestecker","year":"2014","journal-title":"Radiat Oncol Lond Engl"},{"key":"2025112712264191400_tqaf224-B86","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2025112712264191400_tqaf224-B87","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.radonc.2022.10.005","article-title":"Recommendations for radiation therapy in oligometastatic prostate cancer: an ESTRO-ACROP Delphi consensus","volume":"176","author":"Zilli","year":"2022","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"2025112712264191400_tqaf224-B88","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.1016\/j.ijrobp.2024.07.115","article-title":"Assessment of circulating tumor cells in oligometastatic castration-sensitive prostate cancer patients from the ORIOLE trial","volume":"120","author":"Bazyar","year":"2024","journal-title":"Int J Radiat Oncol"},{"key":"2025112712264191400_tqaf224-B89","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s10585-021-10118-7","article-title":"Prospective assessment of AR splice variant and PSMA detection on circulating tumor cells of mCRPC patients: preliminary analysis of patients enrolled in PRIMERA trial (NCT04188275)","volume":"38","author":"Francolini","year":"2021","journal-title":"Clin Exp Metastasis"},{"key":"2025112712264191400_tqaf224-B90","doi-asserted-by":"publisher","first-page":"e2300303","DOI":"10.1200\/PO.23.00303","article-title":"Prospective characterization of circulating tumor cell kinetics in patients with oligometastatic disease receiving definitive intent radiation therapy","volume":"7","author":"Sud","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"2025112712264191400_tqaf224-B91","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1002\/pros.24787","article-title":"Prognostic value of circulating tumor cells in oligorecurrent hormone-sensitive prostate cancer patients undergoing stereotactic body radiation therapy","volume":"84","author":"Matrone","year":"2024","journal-title":"Prostate"},{"key":"2025112712264191400_tqaf224-B92","doi-asserted-by":"publisher","first-page":"933","DOI":"10.3390\/cancers11070933","article-title":"In vivo detection of circulating tumor cells in high-risk non-metastatic prostate cancer patients undergoing radiotherapy","volume":"11","author":"Chen","year":"2019","journal-title":"Cancers (Basel)"},{"key":"2025112712264191400_tqaf224-B93","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41698-021-00211-1","article-title":"Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis","volume":"5","author":"Conteduca","year":"2021","journal-title":"NPJ Precis Oncol"},{"key":"2025112712264191400_tqaf224-B94","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s12920-021-01068-w","article-title":"Genomic analysis of circulating tumor cells in adenosquamous carcinoma of the prostate: a case report","volume":"14","author":"Kitamura","year":"2021","journal-title":"BMC Med Genomics"},{"key":"2025112712264191400_tqaf224-B95","doi-asserted-by":"publisher","first-page":"4143","DOI":"10.1158\/1078-0432.CCR-19-4100","article-title":"Single-cell circulating tumor cell analysis reveals genomic instability as a distinctive feature of aggressive prostate cancer","volume":"26","author":"Malihi","year":"2020","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"2025112712264191400_tqaf224-B96","doi-asserted-by":"publisher","first-page":"4892","DOI":"10.1158\/0008-5472.CAN-20-1216","article-title":"Morphology-predicted large-scale transition number in circulating tumor cells identifies a chromosomal instability biomarker associated with poor outcome in castration-resistant prostate cancer","volume":"80","author":"Schonhoft","year":"2020","journal-title":"Cancer Res"},{"key":"2025112712264191400_tqaf224-B97","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.euo.2024.08.006","article-title":"Liquid biopsy in progressing prostate cancer patients starting docetaxel with or without enzalutamide: a biomarker study of the PRESIDE phase 3b trial","volume":"8","author":"Ruiz-Vico","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"2025112712264191400_tqaf224-B98","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.3390\/cancers14174095","article-title":"The prognostic value of liquid biopsies for benefit of salvage radiotherapy in relapsed oligometastatic prostate cancer","volume":"14","author":"Bogdanova","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2025112712264191400_tqaf224-B99","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1158\/0008-5472.CAN-14-1924","article-title":"Aldehyde dehydrogenase is regulated by \u03b2-catenin\/TCF and promotes radioresistance in prostate cancer progenitor cells","volume":"75","author":"Cojoc","year":"2015","journal-title":"Cancer Res"},{"key":"2025112712264191400_tqaf224-B100","doi-asserted-by":"publisher","first-page":"687","DOI":"10.3109\/09553002.2014.906766","article-title":"CXCR4 as biomarker for radioresistant cancer stem cells","volume":"90","author":"Trautmann","year":"2014","journal-title":"Int J Radiat Biol"},{"key":"2025112712264191400_tqaf224-B101","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1002\/ijc.34457","article-title":"Dynamics of CXCR4 positive circulating tumor cells in prostate cancer patients during radiotherapy","volume":"152","author":"Klusa","year":"2023","journal-title":"Int J Cancer"},{"key":"2025112712264191400_tqaf224-B102","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.cell.2018.11.046","article-title":"Circulating tumor cell clustering shapes DNA methylation to enable metastasis seeding","volume":"176","author":"Gkountela","year":"2019","journal-title":"Cell"},{"key":"2025112712264191400_tqaf224-B103","doi-asserted-by":"publisher","first-page":"108105","DOI":"10.1016\/j.celrep.2020.108105","article-title":"Hypoxia triggers the intravasation of clustered circulating tumor cells","volume":"32","author":"Donato","year":"2020","journal-title":"Cell Rep"},{"key":"2025112712264191400_tqaf224-B104","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.1038\/s41467-021-25189-z","article-title":"ICAM1 initiates CTC cluster formation and trans-endothelial migration in lung metastasis of breast cancer","volume":"12","author":"Taftaf","year":"2021","journal-title":"Nat Commun"},{"key":"2025112712264191400_tqaf224-B105","doi-asserted-by":"publisher","first-page":"e106123","DOI":"10.15252\/embj.2020106123","article-title":"Cell softness regulates tumorigenicity and stemness of cancer cells","volume":"40","author":"Lv","year":"2021","journal-title":"EMBO J"},{"key":"2025112712264191400_tqaf224-B106","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1186\/s12885-015-1478-4","article-title":"Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients","volume":"15","author":"Thalgott","year":"2015","journal-title":"BMC Cancer"},{"key":"2025112712264191400_tqaf224-B107","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s12885-016-2192-6","article-title":"Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer","volume":"16","author":"Lindsay","year":"2016","journal-title":"BMC Cancer"},{"key":"2025112712264191400_tqaf224-B108","doi-asserted-by":"publisher","first-page":"812549","DOI":"10.3389\/fonc.2021.812549","article-title":"Clinical significance of mesenchymal circulating tumor cells in patients with oligometastatic hormone-sensitive prostate cancer who underwent cytoreductive radical prostatectomy","volume":"11","author":"Yang","year":"2021","journal-title":"Front Oncol"},{"key":"2025112712264191400_tqaf224-B109","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1200\/JCO.2014.55.3487","article-title":"Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer","volume":"33","author":"Scher","year":"2015","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2025112712264191400_tqaf224-B110","doi-asserted-by":"publisher","first-page":"5687","DOI":"10.1158\/0008-5472.CAN-17-1353","article-title":"Phenotypic heterogeneity of circulating tumor cells informs clinical decisions between AR signaling inhibitors and taxanes in metastatic prostate cancer","volume":"77","author":"Scher","year":"2017","journal-title":"Cancer Res"},{"key":"2025112712264191400_tqaf224-B111","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.ijrobp.2023.04.010","article-title":"Genomic classifier performance in intermediate-risk prostate cancer: results from NRG oncology\/RTOG 0126 randomized phase 3 trial","volume":"117","author":"Spratt","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025112712264191400_tqaf224-B112","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41586-019-0915-y","article-title":"Neutrophils escort circulating tumour cells to enable cell cycle progression","volume":"566","author":"Szczerba","year":"2019","journal-title":"Nature"},{"key":"2025112712264191400_tqaf224-B113","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1158\/1078-0432.CCR-19-3372","article-title":"T-cell infiltration and adaptive treg resistance in response to androgen deprivation with or without vaccination in localized prostate cancer","volume":"26","author":"Obradovic","year":"2020","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"2025112712264191400_tqaf224-B114","doi-asserted-by":"publisher","first-page":"1055826","DOI":"10.3389\/fendo.2022.1055826","article-title":"Immunosuppressive environment in response to androgen deprivation treatment in prostate cancer","volume":"13","author":"Qin","year":"2022","journal-title":"Front Endocrinol"},{"key":"2025112712264191400_tqaf224-B115","doi-asserted-by":"publisher","first-page":"e0243928","DOI":"10.1371\/journal.pone.0243928","article-title":"Platelet cloaking of circulating tumour cells in patients with metastatic prostate cancer: results from ExPeCT, a randomised controlled trial","volume":"15","author":"Brady","year":"2020","journal-title":"PLoS One"},{"key":"2025112712264191400_tqaf224-B116","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/s0090-4295(98)00637-2","article-title":"Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases","volume":"53","author":"Darson","year":"1999","journal-title":"Urology"},{"key":"2025112712264191400_tqaf224-B117","doi-asserted-by":"publisher","first-page":"4110","DOI":"10.1158\/0008-5472.CAN-20-3595","article-title":"Contacts with macrophages promote an aggressive nanomechanical phenotype of circulating tumor cells in prostate cancer","volume":"81","author":"Osmulski","year":"2021","journal-title":"Cancer Res"},{"key":"2025112712264191400_tqaf224-B118","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13014-020-01577-5","article-title":"Detection and dynamics of circulating tumor cells in patients with high-risk prostate cancer treated with radiotherapy and hormones: a prospective phase II study","volume":"15","author":"Zapatero","year":"2020","journal-title":"Radiat Oncol Lond Engl"},{"key":"2025112712264191400_tqaf224-B119","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1200\/JCO.20.02438","article-title":"Prostate radiotherapy with adjuvant androgen deprivation therapy (ADT) improves metastasis-free survival compared to neoadjuvant ADT: an individual patient meta-analysis","volume":"39","author":"Spratt","year":"2021","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2025112712264191400_tqaf224-B120","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40364-021-00267-y","article-title":"Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer","volume":"9","author":"Zhang","year":"2021","journal-title":"Biomark Res"},{"key":"2025112712264191400_tqaf224-B121","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3390\/cells9010203","article-title":"Androgen receptor and its splicing variant 7 expression in peripheral blood mononuclear cells and in circulating tumor cells in metastatic castration-resistant prostate cancer","volume":"9","author":"Mar\u00edn-Aguilera","year":"2020","journal-title":"Cells"},{"key":"2025112712264191400_tqaf224-B122","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1001\/jamaoncol.2016.1828","article-title":"Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer","volume":"2","author":"Scher","year":"2016","journal-title":"JAMA Oncol"},{"key":"2025112712264191400_tqaf224-B123","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.eururo.2016.07.021","article-title":"Expression of AR-V7 in circulating tumour cells does not preclude response to next generation androgen deprivation therapy in patients with castration resistant prostate cancer","volume":"71","author":"Bernemann","year":"2017","journal-title":"Eur Urol"},{"key":"2025112712264191400_tqaf224-B124","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1373\/clinchem.2016.260299","article-title":"Accession of tumor heterogeneity by multiplex transcriptome profiling of single circulating tumor cells","volume":"62","author":"Gorges","year":"2016","journal-title":"Clin Chem"},{"key":"2025112712264191400_tqaf224-B125","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3390\/cancers12030743","article-title":"Gauging the impact of cancer treatment modalities on circulating tumor cells (CTCs)","volume":"12","author":"Mathias","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2025112712264191400_tqaf224-B126","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/s41377-021-00542-5","article-title":"In vivo flow cytometry reveals a circadian rhythm of circulating tumor cells","volume":"10","author":"Zhu","year":"2021","journal-title":"Light Sci Appl"},{"key":"2025112712264191400_tqaf224-B127","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41586-022-04875-y","article-title":"The metastatic spread of breast cancer accelerates during sleep","volume":"607","author":"Diamantopoulou","year":"2022","journal-title":"Nature"},{"key":"2025112712264191400_tqaf224-B128","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s10585-024-10313-2","article-title":"Multi-marker analysis of circulating tumor cells in localized intermediate\/high-risk and metastatic prostate cancer","volume":"41","author":"Welsch","year":"2024","journal-title":"Clin Exp Metastasis"},{"key":"2025112712264191400_tqaf224-B129","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S1470-2045(15)00054-6","article-title":"Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial","volume":"16","author":"Golden","year":"2015","journal-title":"Lancet Oncol"},{"key":"2025112712264191400_tqaf224-B130","doi-asserted-by":"publisher","first-page":"4213","DOI":"10.3390\/cancers14174213","article-title":"Abscopal response in metastatic melanoma: real-world data of a retrospective, multicenter study","volume":"14","author":"Ollivier","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2025112712264191400_tqaf224-B131","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1158\/0008-5472.113.65.1","article-title":"Particle irradiation suppresses metastatic potential of cancer cells","volume":"65","author":"Ogata","year":"2005","journal-title":"Cancer Res"},{"key":"2025112712264191400_tqaf224-B132","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.drudis.2018.11.017","article-title":"Characterization of circulating tumor cells as a reflection of the tumor heterogeneity: myth or reality?","volume":"24","author":"Brown","year":"2019","journal-title":"Drug Discov Today"},{"key":"2025112712264191400_tqaf224-B133","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.ijrobp.2022.12.035","article-title":"Analysis of a biopsy-based genomic classifier in high-risk prostate cancer: meta-analysis of the NRG oncology\/radiation therapy oncology group 9202, 9413, and 9902 phase 3 randomized trials","volume":"116","author":"Nguyen","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025112712264191400_tqaf224-B134","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1200\/JCO.2025.43.5_suppl.308","article-title":"Gene signature predictor of dose-response to prostate radiation: Validation of PORTOS in phase III trials","volume":"43","author":"Zhao","year":"2025","journal-title":"JCO"},{"key":"2025112712264191400_tqaf224-B135","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/j.ijrobp.2018.06.123","article-title":"Association of circulating tumor cells (CTCs) and genomic signatures in prostate cancer patients","volume":"102","author":"Pollack","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025112712264191400_tqaf224-B136","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1158\/1078-0432.CCR-24-3027","article-title":"PSMA+ extracellular vesicles are a biomarker for SABR in oligorecurrent prostate cancer: analysis from the STOMP-like and ORIOLE trial cohorts","volume":"31","author":"Andrews","year":"2025","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"}],"container-title":["British Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjr\/advance-article-pdf\/doi\/10.1093\/bjr\/tqaf224\/64262459\/tqaf224.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjr\/article-pdf\/98\/1175\/1899\/64262459\/tqaf224.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjr\/article-pdf\/98\/1175\/1899\/64262459\/tqaf224.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T17:26:53Z","timestamp":1764264413000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjr\/article\/98\/1175\/1899\/8253620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,13]]},"references-count":136,"journal-issue":{"issue":"1175","published-online":{"date-parts":[[2025,9,13]]},"published-print":{"date-parts":[[2025,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/bjr\/tqaf224","relation":{},"ISSN":["0007-1285","1748-880X"],"issn-type":[{"value":"0007-1285","type":"print"},{"value":"1748-880X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,9,13]]}}}